Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) was delighted to learn that the US Food and Drug Administration (FDA) is proposing to regulate the level of nicotine in cigarettes and otherwise reduce the health carnage caused by smoking cigarettes. Read the full story here:
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm568923.htm Cigarette smoking kills more people than the use of all other consumer products combined: between 6 million and 7 million every year, worldwide. Every four years, more people die from smoking cigarettes than all military personnel combined from all countries around the world died during World War II.
On Friday July 28, FDA Commissioner Scott Gottlieb said, “The overwhelming amount of death and disease attributable to tobacco is caused by addition to cigarettes – the only legal consumer product that, when used as intended, will kill half of all long-term users.”
But, according to the U.K. National Institute for Health and Care Excellence, “it is primarily the toxins and carcinogens in tobacco smoke – not the nicotine – that causes illness and death.” Lexaria has long held the position that it is the
delivery method itself that is ravaging society. In fact there is limited evidence that suggests small amounts of nicotine can be used to protect against some aspects of Alzheimer’s Disease.
Lexaria’s absorption technology is patent-pending for nicotine delivery through non smokable methods of delivery that, unlike smoking, have zero ability to cause lung cancer and other lung diseases related to smoking or vaping. Scott Gottlieb said the FDA “must also recognize potential for innovation to lead to less harmful products.... (and we are) envisioning a world... where adults who still need or want nicotine could get it from alternative and less harmful sources.”
Lexaria believes its innovative dehydration synthesis technology may be the world’s first to allow for rapid absorption of nicotine through the intestinal wall without causing GI distress, and without being subject to first-pass liver metabolism. Lexaria’s research being conducted at the National Research Council of Canada includes examination of nicotine and/or nicotine analog delivery utilizing its proprietary methodology. Lexaria offers caution that it has not yet performed in-depth studies on the use of its technology with nicotine or nicotine analogs such as the nicotine procrilex commonly found in nicotine gums.
Lexaria’s goal is to provide smokers with a safer alternative that provides the nicotine they crave, without the obvious dangers to health of smoking. We believe nicotine-containing edible consumer products, sold with tightly controlled doses in varying strengths to aid in the gradual weaning away from nicotine, would be the most natural and least harmful method known to lessening the negative health impact to society of cigarette smoking.
And although vaping or e-cigarettes are less harmful than traditional cigarettes, there are still health effects associated with them, not to mention the growing restrictions on use in public places.
In the workplace, smoke breaks are a major hidden cost of employment and many studies have been completed estimating the costs to employers. A consumer product that allows for nicotine delivery without any form of combustion could be consumed without requiring costly smoke breaks. For example one study found that an employee who takes just two 15-minute smoke breaks per day, generates lost productivity costs of $3,077 per year. This of course ignores health care and health insurance costs. A gallup report in 2013 estimated total costs to US employers for smoking absenteeism (smoke breaks) and health care, at $277.9 billion.
Gallup surveyed smokers 25 times between 1977 and 2013 and 74% of respondents replied they would like to quite smoking. Considering that there are roughly 1 billion cigarette smokers in the world, the market demand for a new workable smoking cessation product is immense.
Lexaria is proud to continue its research into more healthful methods to deliver traditionally hard-to-deliver molecules such as nicotine, NSAIDs, cannabinoids and more in the pursuit of better health for everyone.
About Lexaria Lexaria Bioscience Corp. has developed and out-licenses its disruptive technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the USA and in Australia related to edible forms of cannabinoids. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
www.lexariabioscience.com For regular updates, connect with Lexaria on Facebook (
https://www.facebook.com/Lexaria-Corp-106280556370600/) and Twitter (
https://twitter.com/lexariacorp)
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Alex Blanchard, Communications Manager
(778) 796-1897 FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that any additional stock warrants or stock options will be exercised. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition, the patent application and approval process and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that existing capital is sufficient for the Company's needs or that it will be able to raise additional capital. There is no assurance that Lexaria will successfully complete any other contemplated or existing technology license agreements; or that results from any studies will be favorable or in any way support future business activities of any kind. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria Energy Foods, Ambarii, and ViPova
TM products are not intended to diagnose, treat, cure or prevent any disease.
For all the latest news and updates while on the go just text "lexaria" to 76000.
Are you on Twitter, Facebook or Google+? Do not forget to look us up or just click on the buttons below. Give us a follow and a like. Also do not forget to check out our website for all the latest news and updates on Lexaria Bioscience Corp.